JP2019529571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529571A5 JP2019529571A5 JP2019538580A JP2019538580A JP2019529571A5 JP 2019529571 A5 JP2019529571 A5 JP 2019529571A5 JP 2019538580 A JP2019538580 A JP 2019538580A JP 2019538580 A JP2019538580 A JP 2019538580A JP 2019529571 A5 JP2019529571 A5 JP 2019529571A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- functional rna
- rna molecule
- composition
- small molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 23
- 229940126586 small molecule drug Drugs 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 101710148893 Internalin B Proteins 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 108010034429 heregulin alpha Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403595P | 2016-10-03 | 2016-10-03 | |
| US62/403,595 | 2016-10-03 | ||
| PCT/US2017/054884 WO2018067526A1 (en) | 2016-10-03 | 2017-10-03 | Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529571A JP2019529571A (ja) | 2019-10-17 |
| JP2019529571A5 true JP2019529571A5 (OSRAM) | 2020-11-12 |
Family
ID=61831202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538580A Pending JP2019529571A (ja) | 2016-10-03 | 2017-10-03 | 機能性ｒｎａと小分子薬の治療用複合体、およびナノ粒子送達ビヒクル |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190240344A1 (OSRAM) |
| EP (1) | EP3518939A4 (OSRAM) |
| JP (1) | JP2019529571A (OSRAM) |
| CN (1) | CN109890393A (OSRAM) |
| AU (1) | AU2017339456A1 (OSRAM) |
| CA (1) | CA3039040A1 (OSRAM) |
| WO (1) | WO2018067526A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| MX381016B (es) | 2014-01-17 | 2025-03-12 | Cedars Sinai Medical Center | Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro. |
| MX2020006890A (es) * | 2018-01-02 | 2020-09-07 | Cedars Sinai Medical Center | Nanoparticulas para la administracion dirigida de polipeptidos terapeuticos. |
| CN109432430B (zh) * | 2018-11-22 | 2021-12-17 | 华南理工大学 | 一种siRNA和抗癌药物疏水性复合物及其制备方法与应用 |
| JP7698252B2 (ja) * | 2019-09-06 | 2025-06-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 治療薬の核酸媒介性送達 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206285A2 (en) * | 1999-08-09 | 2002-05-22 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
| WO2004029212A2 (en) * | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| US9078927B2 (en) * | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| JP5252618B2 (ja) * | 2007-10-26 | 2013-07-31 | 独立行政法人産業技術総合研究所 | ＲＮＡ干渉効果が高い芳香環修飾ｓｉＲＮＡ |
| WO2010085665A2 (en) * | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| MX381016B (es) * | 2014-01-17 | 2025-03-12 | Cedars Sinai Medical Center | Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro. |
| CA3025348A1 (en) * | 2016-05-27 | 2017-11-30 | Cedars-Sinai Medical Center | Drug-delivery nanoparticles and treatments for drug-resistant cancer |
-
2017
- 2017-10-03 CA CA3039040A patent/CA3039040A1/en not_active Abandoned
- 2017-10-03 JP JP2019538580A patent/JP2019529571A/ja active Pending
- 2017-10-03 AU AU2017339456A patent/AU2017339456A1/en not_active Abandoned
- 2017-10-03 CN CN201780061209.0A patent/CN109890393A/zh active Pending
- 2017-10-03 US US16/338,909 patent/US20190240344A1/en not_active Abandoned
- 2017-10-03 WO PCT/US2017/054884 patent/WO2018067526A1/en not_active Ceased
- 2017-10-03 EP EP17858997.4A patent/EP3518939A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529571A5 (OSRAM) | ||
| Mo et al. | ATP-responsive DNA-graphene hybrid nanoaggregates for anticancer drug delivery | |
| US11242532B2 (en) | Self-assembled 3D RNA cage nanoparticles | |
| Taghdisi et al. | Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes | |
| Zhang et al. | Non-viral nanocarriers for siRNA delivery in breast cancer | |
| Tyagi et al. | Exploiting nanotechnology for the development of microRNA-based cancer therapeutics | |
| Yao et al. | Targeted therapy of colon cancer by aptamer-guided holliday junctions loaded with doxorubicin | |
| CN110573184B (zh) | Rna纳米结构，其制备方法和用途 | |
| JP2019506862A5 (OSRAM) | ||
| JP2015516989A5 (OSRAM) | ||
| EP2700414B1 (en) | Self-gelatinizable nucleic acid | |
| JP2017514800A5 (OSRAM) | ||
| Ngamcherdtrakul et al. | Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment | |
| JP2016511256A5 (OSRAM) | ||
| JP2019517477A5 (OSRAM) | ||
| CN110573166B (zh) | 用于癌症治疗的吉西他滨衍生物 | |
| Song et al. | Self‐Assembled DNA Nanostructures for Biomedical Applications | |
| CN109890393A (zh) | 功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介 | |
| Almalki et al. | Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics | |
| US20190209695A1 (en) | Pharmaceutical Compositions for High-Capacity Targeted Delivery | |
| JP2013530685A5 (OSRAM) | ||
| WO2014194250A3 (en) | Novel nanocarrier delivered cancer chemotherapeutic agents | |
| WO2017162185A1 (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| Udappusamy et al. | Nanoparticle-Mediated Delivery of siRNA: Targeting Gene Silencing in Cancer Therapy | |
| JP2016533190A5 (OSRAM) |